Leica Biosystems Launches Cutting-Edge Digital Pathology Software at ECP 2025, Further Enhancing Extensive Suite of Solutions
VISTA, California, September 5, 2025 — In a major leap forward to enable digital transformation of clinical diagnostics, Leica Biosystems proudly showcases its latest, trailblazing additions to the Aperio Digital Pathology portfolio at booth #121 during the 37th European Congress of Pathology.
The new clinical image management software, Aperio HALO AP, delivers a full suite of enterprise-grade digital pathology diagnostic workflows for on-screen diagnosis, multi-disciplinary team meetings, consultations, and more.
Exclusively available via Aperio HALO AP, the Aperio AI Store is a scalable analysis platform, enabling pathologists to leverage a range of powerful applications developed by leading innovation partners, including Histofy, Indica Labs and Lunit, seamlessly embedded in a single interface.
“The launch of Aperio HALO AP and Aperio AI Store marks a significant advancement in Leica Biosystems diagnostic digital pathology platform,” said Naveen Chandra, Vice President and General Manager of Digital Pathology at Leica Biosystems. “We are committed to delivering comprehensive world-class computational pathology solutions to accelerate pathology diagnoses, provide deeper insights, and ultimately improve patient outcomes.”
Indica Labs CEO Steven Hashagen commented, "We are proud to partner with Leica Biosystems in the introduction of these latest innovations in digital pathology. As a pioneer in the field, we continue to push boundaries by combining deep expertise in computational pathology with cutting-edge artificial intelligence. By harnessing the power of AI, we are not only enhancing analytical capabilities but also helping to ensure that patients receive faster, more accurate diagnoses and more personalized treatment pathways.”
For pharma companies that need to quickly integrate diagnostic algorithms into an end-to-end computational pathology workflow, the Aperio AI Store provides the highest level of interoperability to rapidly deploy algorithms on Aperio HALO AP and accelerate program timelines. This flexible and open approach enables pharma partners to seamlessly integrate industry-leading algorithms into Aperio HALO AP and the Aperio AI Store.
In addition to Aperio HALO AP and Aperio AI Store, we welcome you to join us at ECP and see our other systems in action.
- Aperio GT 450 DX world-leading clinical scanner with new manual scan functionality, enabling users to accurately capture faintly stained, or small fragments of tissue
- Aperio GT 180 scanner for high-speed, high-quality brightfield scanning
- Aperio iQC software delivering consistent and standardized WSI quality control
- HALO Link a flexible, study-centric IMS leveraged by organizations worldwide to manage their research
Aperio HALO AP is CE IVDR-marked for in-vitro diagnostic use. Not all products shown may be available for use in your country.
About Leica Biosystems
Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.
